CC-Pharming And iBio Expand Chinese Rituximab Venture
Executive Summary
A year after their initial tie-up, US plant-based tech firm iBio Inc. and China’s CC-Pharming Ltd are expanding their collaboration on developing a plant-derived bio-better rituximab candidate for the Chinese market.